De Lisle Partners LLP Roivant Sciences Ltd. Transaction History
De Lisle Partners LLP
- $602 Billion
- Q1 2025
A detailed history of De Lisle Partners LLP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, De Lisle Partners LLP holds 50,000 shares of ROIV stock, worth $563,500. This represents 0.08% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$563,500
Previous $592 Million
14.79%
% of portfolio
0.08%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding ROIV
# of Institutions
332Shares Held
496MCall Options Held
3.67MPut Options Held
754K-
Qvt Financial LP New York, NY65.8MShares$741 Million69.8% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X061.9MShares$697 Million5.69% of portfolio
-
Viking Global Investors LP46MShares$519 Million1.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.8MShares$459 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.9MShares$405 Million0.03% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.94B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...